Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors

Liver

Volumn 17, Issue 1, 1997, Pages 24-29

  Tsai, Jung Fa ^a   Jeng, Jen Eing ^a   Ho, Mei Shang ^b   Wang, Ching Shan ^c   Chang, Wen Yu ^a   Hsieh, Min Yuh ^a   Lin, Zu Yau ^a   Tsai, Juei Hsiung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c Kaohsiung Blood Donation Center   (Taiwan)

Author keywords

Antibody to hepatitis C virus; Hepatitis B surface antigen; Serum alanine aminotransferase; Volunteer blood donors

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; RISK FACTOR;

EID: 0031043777     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1997.tb00774.x     Document Type: Article

References (41)

1. SHERLOCK S, DOOLEY J. Disease of the liver and biliary system, 9th edn. Oxford: Blackwell Scientific Publications, 1993: 260-292.
2. YANO M, YATSUHASHI H, INOUE O, INOKUCHI K, KOGA M. Epidemiology and long-term prognosis of hepatitis C virus infection in Japan. Gut 1993: 34 (Suppl 2): S13-S16.
3. BROTMAN B, PRINCE A M. Gamma-glutamyl transpeptidase as a potential surrogate marker for the detection of non-A, non-B carrier state. Vox Sang 1988: 57: 144-147.
4. CHEUNG R C, CHAN R T, LOK A S F. Longitudinal study of hepaatitis C viremia in chronic hepatitis C. J Med Virol 1993: 41: 338-342.
5. KIYOSAWA K, TANAKA E, SODEYAMA T, et al. Natural history of hepatitis C. Intervirology 1994: 37: 101-107.
6. KOZIOL D E, HOLLAND P V, ALLING D W. et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 1986: 104: 488-495.
7. WIDELL A, SUNDSTROM G, HANSSON B G, et al. Relation between donor transaminase and recipient hepatitis non-A, non-B in Sweden. Vox Sang 1988: 54: 154-159.
8. TAKANO S, OMATA M, OHTO M, et al. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis. Hepatology 1993: 18: 235-239.
9. LIN-CHU M, TSAI S J L, WATANABE J, et al. The prevalence of anti-HCV among Chinese blood donors in Taiwan. Transfusion 1990: 30: 471-473.
10. VAN DER POEL C L. Hepatitis C virus infection from blood and blood products FEMS Microbiol Rev 1994: 14: 241-246.
11. ALTER M J. Review of serologic testing for hepatitis C virus infection and risk of post-transfusion hepatitis C. Arch Pathol Lab Med 1994: 118: 342-345.
12. YUKI N, HAYASHI N, HAGIWARA H, et al. Hepatitis C virus antibodies and virus replication in asymptomatic blood donors. Vox Sang 1994: 67: 280-285.
13. ROSSINI A, GAZZOLA GB, RAVAGGI A, et al. Long-term follow-up and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. Transfusion 1995: 35: 108-111.
14. FUJIYAMA S, KAWANO S, SATO S, et al. Evaluation of three hepatitis C virus-related antibodies ClOO, KCL-163, JCC: test for screening blood donors. Dig Dis Sci 1992: 37: 1489-1494.
15. HOOFNAGLE J H, SHAFRITZ D A, POPPER H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987: 7: 758-763.
16. BRIERE R O, Serum ALT levels: Effects of sex, race and obesity on rejection rates. Transfusion 1988: 28: 392-393.
17. HANSON M, POLESKY H F. Factors effecting alanine amino-transferase in blood donors. In: Hopkins R, Field S, eds. Proceedings of the international hepatitis workshops. Edinburgh: Nuclear Enterprises Ltd, 1982: 93-97.
18. TSAI J F, MARGOLIS H S, JENG J E. et al. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol 1995: 75: 39-44.
19. TSAI J F, JENG J E, CHANG W Y. et al. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine 1995: 74: 136-143.
20. JENG J E, TSAI J F. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 1991: 34: 74-77.
21. TSAI J F, CHANG W Y, JENG J E, et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993: 41: 296-300.
22. TSAI J F, CHANG W Y, JENG J E, et al. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994: 14: 98-102.
23. TSAI J F, JENG J E, HO M S, et al. Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: a case-control study. Int J Cancer 1994: 56: 619-621.
24. TSAI J F, CHANG W Y, JENG J E, et al. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol 1994: 44: 92-95.
25. TSAI J F, JENG J E, CHANG W Y, et al. Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B. Scand J Gastroenterol 1994: 29: 550-552.
26. TSAI J F, CHANG W Y, JENG J E, et al. Frequency of raised α-fetoprotein level among Chinese patients with hepatocellular carcinoma. Br J Cancer 1994: 69: 1157-1159.
27. TSAI J F, MARGOLIS H S, JENG J E. et al. Association between hepatitis B and C virus infection and Chinese hepatocellular carcinoma. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 697-700.
28. TSAI J F, JENG J E, CHANG W Y, et al. Antibodies to hepatitis E virus among Chinese patients with acute hepatitis in Taiwan. J Med Virol 1994: 43: 341-344.
29. TSAI J F, JENG J E, CHANG W Y, et al. Circulating immune complexes in chronic hepatitis C. J Med Virol 1995: 46: 12-17.
30. TSAI J F, JENG J E, HO M S, et al. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol 1996: 24: 271-276.
31. TSAI J F, JENG J E, HO M S, et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996: 73: 1498-1502.
32. MCGUINNESS P H, BISHOP G A, LIEN A, et al. Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. Hepatology 1993: 18: 485-490.
33. ROMEO J M, ULRICH P P, BUSCH M P, et al. Analysiss of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors. Hepatology 1993: 17: 188-195.
34. ZANELLA A, CONTE D, PRATI D, et al. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. Hepatology 1995: 21: 913-917.
35. CHU C M, SHEEN I S, LIN S M, et al. Sex differences in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis 1993: 16: 709-713.
36. MACLENNAN S, MOORE M C, HEWITT P E, et al. A study of anti-hepatitis C positive blood donors: the first year of screening. Transfusion Med 1994: 4: 125-133.
37. PATINO-SARCINELLI F, HYMAN J, CAMACHO L A, et al. Prevalence and risk factors for hepatitis C antibodies in volunteer blood donors in Brazil. Transfusion 1994: 34: 138-141.
38. SHEU J C, WANG J T, WANG T H, et al. Prevalence of hepatitis C viral infection in a community in Taiwan: detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993: 17: 192-198.
39. CHEN D S. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol 1993: 8: 470-475.
40. LIN H H, HSU H Y, CHANG M H, et al. Low prevalence of hepatitis C virus and infrequent perinatal or spouse infections in pregnant women in Taiwan. J Med Virol 1991: 35: 237-240.
41. WU J C, LIN H C, JENG F S, et al. Prevalence, infectivity, and risk factor analysis of hepatitis C virus infection in prostitutes. J Med Virol 1993: 39: 312-317.